Moderna Stock Price, News & Analysis

Moderna (NASDAQ:MRNA) closed a five-year non-dilutive term loan facility for up to $1.5 billion with Ares Management Credit Funds on November 20, 2025.

The facility includes a $600 million initial term loan funded at closing, a $400 million delayed-draw term loan available through November 2027, and an additional $500 million delayed-draw tranche available through November 2028 that is contingent on achievement of key regulatory milestones aligned with Moderna's late-stage clinical pipeline.

Moderna reiterated its 2025 financial guidance and reaffirmed a target to reach cash breakeven by 2028. The company also scheduled an Analyst Day webcast for November 20, 2025 at 9:00 a.m. ET.

Moderna (NASDAQ:MRNA) is expanding U.S. manufacturing by onshoring Drug Product capabilities to its Moderna Technology Center in Norwood, Massachusetts. The project includes a >$140 million investment and is expected to create hundreds of biomanufacturing jobs, enabling full end-to-end mRNA manufacturing in the U.S. for commercial and clinical supply. Construction has started and Moderna is targeting completion by the first half of 2027. The move reinforces Moderna's domestic manufacturing footprint and supports its pipeline of mRNA vaccines and therapeutics across infectious diseases, cancer, rare diseases, and autoimmune disorders.

Moderna (Nasdaq: MRNA) will present at Piper Sandler's 37th Annual Healthcare Conference on Tuesday, December 2, 2025 at 11:00 AM ET. A live webcast of the presentation will be available under Events and Presentations in the Investors section at investors.modernatx.com. A replay will be archived on Moderna's website for at least 30 days following the presentation.

Moderna (NASDAQ:MRNA) reported Q3 2025 revenue of $1.0B, a GAAP net loss of $200M and GAAP EPS of $(0.51). The company narrowed 2025 revenue guidance to $1.6–$2.0B, improved expected GAAP operating expenses by $0.7B to $5.2–$5.4B, and raised year-end cash projections to $6.5–$7.0B. Cash and investments were $6.6B as of September 30, 2025.

Commercially, Q3 COVID vaccine sales were $971M (U.S. $781M, international $190M); mNEXSPIKE received FDA approval for older adults and certain adults with risk factors and is approved in 40 countries. RSV vaccine mRESVIA generated $2M in Q3 and is approved in 40 countries for 60+ adults. Clinical updates include discontinuation of congenital CMV after a Phase 3 miss, norovirus Phase 3 accrual delays, and multiple late‑stage oncology and rare‑disease milestones on track.

Moderna (NASDAQ:MRNA) announced on November 3, 2025 that the first patient has been dosed in a Phase 1/2 dose‑escalation study of mRNA‑2808, an investigational mRNA‑based T‑cell engager (TCE) for relapsed or refractory multiple myeloma (RRMM).

mRNA‑2808 encodes three TCEs that target three validated myeloma‑associated antigens to address tumor heterogeneity and potential target‑mediated resistance. The first dose was given at SCRI Oncology Partners in Nashville in collaboration with Sarah Cannon Research Institute. The study (NCT07116616) will evaluate safety and tolerability in adults aged 18 and older.

Moderna (NASDAQ:MRNA) was named a top employer in the global biopharmaceutical industry by Science and Science Careers in the 2025 Top Employers Survey for the eleventh consecutive year. The recognition cites Moderna's focus on innovation, employee-centered culture and investments in advanced manufacturing hubs in Australia, Canada and the United Kingdom. In 2025 Moderna received approval for its third product, mNEXSPIKE, a COVID-19 vaccine for adults 65+ and ages 12–64 with specified risk factors.

The survey was based on ~5,500 completed responses, primarily from North America, Europe and Asia/Pacific Rim.

Moderna (Nasdaq: MRNA) will host an Investor Event - Analyst Day at 9:00 a.m. ET on Thursday, November 20, 2025.

Management will present on Moderna's development and commercial strategy and key business considerations. A live webcast will be available at investors.modernatx.com under Events and Presentations. A replay will be archived on Moderna's website for at least 30 days following the presentation.

Moderna (NASDAQ: MRNA) announced that its Phase 3 pivotal trial of investigational CMV vaccine mRNA-1647 did not meet the primary efficacy endpoint in seronegative women aged 16–40, and the company will discontinue its congenital CMV development program.

The randomized, observer-blind, placebo-controlled trial enrolled ~7,500 women across ~300 sites in 13 countries. Vaccine efficacy against primary CMV infection ranged from 6% to 23% depending on case definition. mRNA-1647 was generally well tolerated and no safety concerns were reported by the Data and Safety Monitoring Board. Moderna will continue a Phase 2 study of mRNA-1647 in bone marrow transplant patients and does not expect any impact to its 2025 financial guidance or its expectation of achieving breakeven in 2028.

Moderna (NASDAQ:MRNA) announced presentations of clinical data for two influenza vaccine candidates at IDWeek 2025 (Oct 19-22, 2025) in Atlanta.

mRNA-1010: Late-breaking data in adults ≥50 showed relative vaccine efficacy (rVE) versus a licensed standard-dose influenza vaccine of 26.6% (95% CI: 16.7%, 35.4%), meeting prespecified superiority; rVE against medically-attended/severe influenza was 33.7% (95% CI: 12.0, 50.0%). The candidate was described as well-tolerated; most common solicited adverse reactions were injection site pain, fatigue, headache, and myalgia.

mRNA-1018: Phase 1/2 dose-ranging data in adults ≥18 showed rapid, persistent immune responses with 97.8% of participants meeting seroprotective levels three weeks after the second dose (95% CI: 95.4, 99.2); 79.5% reached protective levels three weeks after the first dose and 70.6% maintained seroprotective titers six months after dose two (95% CI: 64.8, 76.0).